About me

I advise early to mid-size rare disease and gene therapy companies at the critical decision points that shape long-term program success.

My work supports leadership teams to see beyond product approval and create the steps for stronger choices around endpoint selection, trial population, evidence strategy, expanded access, and post-approval readiness.

I enjoy being outside in my favorite part of the world, the Pacific Northwest, with my family and friends!